Ziprasidone (GEODON): oral versus IM renal limits

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use

Oral no-adjustment does not clear the IM excipient risk

Oral renal PK and the IM cyclodextrin vehicle concern are different questions. The IM formulation lacks comparable renal study data.

Before applying: Confirm route and formulation. Do not infer an IM dose adjustment or safety from the oral statement.

Also check: Oral no-adjustment does not clear the IM excipient risk

Rxlist source

GlobalRPh RX List - GEODON

Product / population: Single-agent GEODON oral product with a separately identified IM formulation caution.
Renal measure: Qualitative renal impairment; oral and intramuscular data differ.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

The oral product does not require a renal dose reduction based on the selected pharmacokinetic evidence. The intramuscular formulation has not been systematically studied in renal impairment and warrants caution because its cyclodextrin vehicle is cleared by renal filtration. Do not apply the oral no-adjustment statement to the IM excipient risk. This excerpt supplies no renal-specific IM regimen.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/geodon-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - GEODON

No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.

Single-agent GEODON oral product with a separately identified IM formulation caution.

Renal method: Qualitative renal impairment; oral and intramuscular data differ.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Read 1 difference / caution notes Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

route and excipient

Oral no-adjustment does not clear the IM excipient risk

Oral renal PK and the IM cyclodextrin vehicle concern are different questions. The IM formulation lacks comparable renal study data.

How to use this: Confirm route and formulation. Do not infer an IM dose adjustment or safety from the oral statement.

GlobalRPh RX List - GEODON

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

Rxlist source

GlobalRPh RX List - GEODON

Single-agent GEODON oral product with a separately identified IM formulation caution.

Method: Qualitative renal impairment; oral and intramuscular data differ.

Renal dosing, restrictions and evidence limits Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope GlobalRPh RX List - GEODON

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/geodon-drug/

Exact product and population

Single-agent GEODON oral product with a separately identified IM formulation caution.

RDM37-SCOPE-ziprasidone-geodon · Source section: Selected source product scopeRenal section finder

Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist Compare this source

GlobalRPh RX List - GEODON

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Single-agent GEODON oral product with a separately identified IM formulation caution.

Renal method: Qualitative renal impairment; oral and intramuscular data differ.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.

No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

RDM37-rxlist-ziprasidone-geodon-1222a6cc07-C1 · Source locator: Use in Specific Populations: Renal Impairment.

Source identity and provenance

Source family: product_label_mirror
Source: https://globalrph.com/rx-list/geodon-drug/
Retrieved: 2026-09-07
Renal-function method: Qualitative renal impairment; oral and intramuscular data differ.
Source date/version: Source revision date not established in selected retrieval.
Hash meaning: SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256: 085a1cc488d10db513c2b7b96db3db04841ed4066ec9177327b007178fe0fcb2

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://globalrph.com/rx-list/geodon-drug/
Source retrieval: 2026-09-07. This is not the source publication or label revision date.
Original source type: rxlist summary
Local text SHA-256: b6c908c8e45d4edf98bb90e74bd0859c0d141691ebaf06c6b90fd570f59e68f4
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report